title: Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer.
abstract: OBJECTIVE
  We studied cisplatin plus gemcitabine as induction (neoadjuvant) therapy in patients with stage III non-small cell lung cancer (NSCLC) to assess its objective remission rate, resectability, survival, and toxicity.
  
  
  METHODS
  Patients with stage III NSCLC received 2 cycles of gemcitabine 1250 mg/m2 on days 1, 8, and 15, plus cisplatin 100 mg/m2 on day 2. Subsequently, patients were assigned to local therapy--surgery or radiotherapy.
  
  
  RESULTS
  Twenty-nine eligible patients (male/female: 21/8) with a median age of 59 years (range, 43-71 years) were enrolled between October 1996 and February 1999. A total of 80 cycles were given, with a median of 3 per patient (range, 1-4 cycles). Overall, toxicities were mild; only one patient had febrile neutropenia, and there were no grade 4 non-hematological toxicities. There was one toxic death following afebrile grade 4 neutropenia. Overall clinical response rate (2 complete responses [CRs] + 16 partial responses [PRs]) was 62% (95% CI, 45%-79%); 10 patients had stable disease and none progressed; one patient was not evaluable. Eight of the 18 operated patients had pathological response: 1 CR and 7 downstagings to N(-); 14 patients were resected. Median survival was 17 months (95% CI, 13-21 months), with 1-year and 2-year actuarial survival rates of 61% and 29%, respectively.
  
  
  CONCLUSIONS
  Gemcitabine plus cisplatin is a very active and well-tolerated induction regimen in stage III NSCLC. Comparative studies with other standard regimens are warranted.
authors.affiliation: Alexander Fleming Institute, Buenos Aires, Argentina. mvankooten@intramed.net.ar
authors.forename: Maximiliano
authors.initials: M
authors.lastname: Van Kooten
authors.forename: Moisés
authors.initials: M
authors.lastname: Rosenberg
authors.forename: Mauro
authors.initials: M
authors.lastname: Orlando
authors.forename: José
authors.initials: J
authors.lastname: Morero
authors.forename: Manuel
authors.initials: M
authors.lastname: Vilanova
authors.forename: Oscar
authors.initials: O
authors.lastname: Rojas
authors.forename: Héctor
authors.initials: H
authors.lastname: Vicente
authors.forename: Claudia
authors.initials: C
authors.lastname: Bagnes
authors.forename: Carlos
authors.initials: C
authors.lastname: Silva
authors.forename: Reinaldo D
authors.initials: RD
authors.lastname: Chacón
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods* / Q000706:statistics & numerical data; D009367:Neoplasm Staging; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine